Location on site: Resources section Estimated length: ~4,800–5,200 words
1. Introduction to Myxomatous Mitral Valve Disease (MMVD)
Myxomatous Mitral Valve Disease (MMVD) is a chronic, progressive degenerative disease of the mitral valve and represents the most common acquired heart disease in dogs. Also referred to as myxomatous degeneration, endocardiosis, or chronic valvular heart disease, MMVD accounts for approximately 75% of all diagnosed canine cardiac disease cases worldwide.
The condition is characterized by gradual structural deterioration of the mitral valve apparatus, leading to mitral regurgitation (MR)—the backward leakage of blood from the left ventricle into the left atrium during systole. While MMVD can affect dogs of any size or breed, it is particularly prevalent in small and toy breed dogs, with some breeds demonstrating an exceptionally high lifetime risk.
MMVD is inherently progressive, though the rate of progression varies widely between individuals. Many dogs remain asymptomatic for years after the initial murmur is detected, while others progress more rapidly to congestive heart failure (CHF). Importantly, the disease process begins long before clinical signs are evident. Structural cardiac changes, such as left atrial enlargement and ventricular remodeling, often precede symptoms by months to years.
This prolonged preclinical phase represents a critical window for early detection and intervention. Advances in diagnostic imaging—particularly thoracic radiography and echocardiography—have allowed veterinarians to identify dogs at higher risk of developing CHF and to initiate evidence-based therapy at the optimal time. Landmark studies, such as the EPIC trial, have demonstrated that appropriate treatment during the preclinical stage can significantly delay the onset of heart failure and extend both survival time and quality of life.
For general practitioners, specialists, and informed pet owners alike, understanding MMVD requires more than simply recognizing a heart murmur. Accurate staging, informed by tools such as the ACVIM classification system, Vertebral Heart Score (VHS), and Vertebral Left Atrial Size (VLAS), is essential for guiding monitoring strategies, treatment decisions, and client communication.
This comprehensive guide provides a step-by-step veterinary overview of MMVD—from underlying pathophysiology to advanced-stage management—designed to support confident, evidence-based care at every stage of the disease.
2. Pathophysiology: What Happens in MMVD
Normal Mitral Valve Anatomy and Function
The mitral valve lies between the left atrium (LA) and left ventricle (LV) and consists of two thin leaflets anchored by the chordae tendinae to the papillary muscles. During diastole, the valve opens to allow blood flow from the atrium into the ventricle. During systole, it closes tightly, preventing retrograde blood flow and ensuring efficient forward cardiac output.
Myxomatous Degeneration Process
In MMVD, the mitral valve undergoes a progressive degenerative change known as myxomatous degeneration. This process involves:
- Accumulation of glycosaminoglycans within the valve matrix
- Disruption of collagen architecture
- Thickening and nodular deformation of valve leaflets
- Elongation and weakening of the chordae tendinae
As degeneration advances, the valve leaflets lose their normal pliability and structural integrity. They become bulky and may prolapse into the left atrium during systole, preventing proper coaptation.
Development of Mitral Regurgitation
Incomplete valve closure results in mitral regurgitation, where a portion of each systolic blood volume flows backward into the left atrium. The severity of regurgitation depends on the extent of valvular deformation, annular dilation, and chordal dysfunction.
Volume Overload Cascade
Chronic mitral regurgitation initiates a compensatory cascade:
-
Left atrial volume overload
- Increased atrial pressure and dilation
- Predisposes to pulmonary venous congestion
-
Left ventricular eccentric hypertrophy
- Increased diastolic filling volume
- Ventricular dilation with relatively preserved wall thickness
-
Progressive remodeling and dysfunction
- Increased myocardial oxygen demand
- Eventual decline in systolic and diastolic performance
Progression to Congestive Heart Failure
As compensatory mechanisms become exhausted, elevated left atrial pressures are transmitted backward into the pulmonary circulation, resulting in pulmonary edema. This marks the transition from preclinical MMVD to clinical congestive heart failure (CHF).
Hemodynamic Consequences Simplified
- Mild disease: Compensation maintains normal cardiac output
- Moderate disease: Cardiac enlargement without clinical signs
- Advanced disease: Elevated filling pressures → fluid accumulation → CHF
Understanding this pathophysiologic continuum is essential for interpreting imaging findings and implementing stage-appropriate therapy.
3. Breed Predisposition & Risk Factors
MMVD demonstrates a strong breed, age, and sex predilection, supporting a significant genetic component to disease development.
High-Risk Breeds
Breeds with the highest documented prevalence include:
- Cavalier King Charles Spaniel (CKCS) – extremely high prevalence; often early onset
- Dachshund
- Miniature and Toy Poodles
- Chihuahua
- Maltese
- Yorkshire Terrier
- Pomeranian
- Cocker Spaniel
- Miniature Schnauzer
Breed-specific disease timelines and screening recommendations are discussed in our individual breed-specific cardiac guides.
Age as a Primary Risk Factor
MMVD is primarily a disease of aging dogs. Prevalence increases dramatically after 7–8 years of age, though CKCS may develop murmurs much earlier.
Sex Predisposition
Male dogs are affected approximately 1.5 times more frequently than females and often experience faster disease progression.
Genetic Factors
Inheritance patterns are complex and polygenic. In CKCS, MMVD is considered highly heritable, prompting ongoing efforts toward selective breeding and early screening programs.
Why Small Breeds Are More Affected
The exact reason remains unclear, but hypotheses include:
- Differences in connective tissue metabolism
- Valve size-to-stress relationships
- Genetic selection pressures in toy breeds
Large Breed Considerations
While less common, MMVD does occur in large breeds such as Doberman Pinschers and Great Danes. In these dogs, differentiating MMVD from dilated cardiomyopathy (DCM) is especially important, as management strategies differ significantly.
4. Clinical Signs of MMVD
Clinical presentation varies widely depending on disease stage.
Early / Asymptomatic Stage
Most dogs with MMVD are initially asymptomatic. The only clinical finding is often a heart murmur.
- Left apical systolic murmur
- Typically plateau-shaped
- Graded using a I–VI scale
- Murmur intensity does not always correlate with disease severity
Intermediate Stage
As cardiac remodeling progresses:
- Decreased exercise tolerance
- Mild, intermittent cough (often nocturnal)
- Subtle increase in resting respiratory rate
- Occasional tachypnea during exertion
These signs are frequently misattributed to aging or respiratory disease.
Advanced Stage
Dogs with advanced MMVD and CHF may exhibit:
- Persistent or worsening cough
- Dyspnea and tachypnea
- Orthopnea (difficulty breathing when lying down)
- Marked exercise intolerance
- Syncope or collapse
- Abdominal distension due to ascites (right-sided involvement)
- Weight loss and muscle wasting (cardiac cachexia)
- Cyanosis in severe cases
Heart Failure Indicators
A key objective marker is resting respiratory rate (RRR):
- Normal: <30 breaths/min
- Concerning: 30–40 breaths/min
- Emergency: >40 breaths/min
For a full overview, see our heart disease symptoms guide.
5. ACVIM Staging System for MMVD
The American College of Veterinary Internal Medicine (ACVIM) staging system standardizes MMVD classification and guides treatment decisions.
Stage A – At-Risk Patients
Definition: Dogs at risk, no structural disease
- Predisposed breed
- No murmur, no cardiomegaly
Examples: Young CKCS without murmur
Treatment: None
Monitoring: Annual auscultation
Imaging: Baseline VHS/VLAS recommended
Stage B – Preclinical MMVD
Structural disease present, no clinical signs.
Stage B1
Criteria:
- Heart murmur present
- No or minimal cardiomegaly
- VHS <10.5 (breed-adjusted)
- VLAS <2.5
- Echo:
- LA:Ao <1.6
- LVIDdN <1.7
Treatment: None proven beneficial
Monitoring: Every 6–12 months
Stage B2
Criteria:
- Murmur ≥ Grade III/VI
- Significant cardiomegaly
Radiographic (no echo):
- VHS ≥11.5 OR
- VLAS ≥3.0
Echocardiographic:
- LA:Ao ≥1.6
- AND LVIDdN ≥1.7
Treatment: Pimobendan (EPIC evidence)
Monitoring: Every 4–6 months
Stage C – Congestive Heart Failure
Definition: Current or past CHF
Treatment: Quadruple therapy
- Furosemide
- Pimobendan
- ACE inhibitor
- Spironolactone
Monitoring: Frequent reassessment
Stage D – Refractory Heart Failure
Definition: CHF despite standard therapy
Treatment: Intensified diuresis, advanced interventions
Prognosis: Guarded
MMVD Staging Overview Table
| Stage | Murmur | Cardiomegaly | Clinical Signs | Treatment |
|---|---|---|---|---|
| A | No | No | No | None |
| B1 | Yes | No | No | None |
| B2 | Yes | Yes | No | Pimobendan |
| C | Yes | Yes | Yes | CHF therapy |
| D | Yes | Yes | Refractory | Advanced care |
6. The Role of VHS in MMVD Staging
The Vertebral Heart Score (VHS) is a cornerstone of MMVD assessment using thoracic radiographs.
Why VHS Matters
- Quantifies overall cardiac size
- Widely accessible
- Repeatable for serial monitoring
VHS ≥11.5: Evidence Base
A VHS threshold of 11.5 has been shown to correlate strongly with the onset of CHF in MMVD and is incorporated into ACVIM Stage B2 criteria.
Breed-Adjusted VHS
Normal VHS values vary by breed. Using breed-specific references improves accuracy and reduces overdiagnosis.
Serial VHS Monitoring
- Progressive increases predict disease progression
- Rapid changes warrant closer monitoring
- Useful for determining when to escalate from B1 to B2
Limitations
- Does not differentiate chamber enlargement
- Influenced by positioning and respiration
For a detailed guide, visit our VHS complete guide.
7. The Role of VLAS in MMVD Staging
Why Left Atrial Size Matters
Left atrial enlargement reflects chronic volume overload and correlates closely with CHF risk.
VLAS ≥3.0 as Stage B2 Criterion
VLAS provides a simple radiographic surrogate for echocardiographic LA:Ao ratio.
Diagnostic Performance
Studies demonstrate strong sensitivity and specificity for detecting significant LA enlargement using VLAS.
When VLAS Is Especially Useful
- Echocardiography unavailable
- Rapid screening in general practice
- Serial monitoring over time
Combined VHS + VLAS Value
Using both metrics improves staging accuracy and clinical confidence.
Learn more in our VLAS complete guide.
8. Diagnostic Workup for MMVD
Physical Examination
- Murmur characterization
- Pulse quality
- Respiratory assessment
Thoracic Radiography
Views: Right lateral and DV/VD
Assess:
- Cardiac silhouette
- Pulmonary vasculature
- Pulmonary edema
- Measure VHS and VLAS
Echocardiography
Gold standard for diagnosis:
- 2D: valve morphology, chamber size
- M-mode: ventricular dimensions
- Doppler: MR severity
Electrocardiography
- Detect arrhythmias
- Baseline rhythm assessment
Biomarkers
- NT-proBNP: cardiac stretch
- Cardiac troponin: myocardial injury
Referral Indications
- Uncertain staging
- Rapid progression
- Stage B2 confirmation
- Refractory CHF
9. Treatment Overview by Stage
No Treatment: Stage A & B1
- No evidence supporting early drug therapy
- Focus on monitoring and education
Pimobendan: Stage B2+
Mechanism: Inodilator
- PDE3 inhibition
- Calcium sensitization
Dose: 0.25–0.3 mg/kg PO q12h
EPIC Study:
- ~60% longer preclinical period
- Delayed onset of CHF
Heart Failure Management: Stage C/D
Furosemide:
- Primary diuretic
- Monitor renal values and electrolytes
ACE Inhibitors:
- Enalapril, benazepril
Spironolactone:
- Aldosterone antagonism
- Cardioprotective effects
Additional Measures:
- Dietary sodium restriction
- Weight management
- Balanced exercise
10. Prognosis and Disease Progression
Prognostic Factors
- Stage at diagnosis
- Rate of cardiac enlargement
- Response to therapy
- Owner compliance
Median Survival Times
- Stage B2: Often years with treatment
- Stage C: ~1–2 years (variable)
- Stage D: Months to a year
Quality of Life
Early intervention and careful monitoring can maintain excellent quality of life for prolonged periods.
Client Communication
Clear staging explanations help set realistic expectations and improve adherence.
11. Frequently Asked Questions (FAQs)
“My dog has a murmur but seems fine—should I worry?”
Not all murmurs indicate advanced disease, but evaluation and monitoring are essential.
“How quickly does MMVD progress?”
Progression varies widely—from months to many years.
“Can MMVD be prevented?”
No, but early detection and appropriate therapy slow progression.
“What is the life expectancy with MMVD?”
Many dogs live normal lifespans, especially with timely treatment.
“When should my dog see a cardiologist?”
At Stage B2, uncertain diagnosis, or if CHF develops.
12. Conclusion
Myxomatous Mitral Valve Disease is a common, progressive, but manageable condition when diagnosed and staged appropriately. Understanding the pathophysiology, recognizing breed and age risk factors, and applying the ACVIM staging system allow clinicians to intervene at the optimal time.
Accessible imaging tools such as VHS and VLAS empower general practitioners to accurately identify dogs at risk for progression and initiate evidence-based therapy—often before clinical signs develop.
Consistent monitoring, clear client communication, and timely treatment significantly improve both survival and quality of life. Tools like RadAnalyzer support standardized, repeatable measurements, making long-term MMVD management more precise and proactive.
Early detection changes outcomes—and in MMVD, staging truly matters.
Related Resources
- VHS: Vertebral Heart Score Complete Guide — Learn how VHS measurements help stage MMVD progression.
- VLAS: Vertebral Left Atrial Size Guide — Understand how VLAS complements VHS in detecting left atrial enlargement.
- ACVIM MMVD Guidelines Summary — Review the latest consensus guidelines for MMVD staging and treatment.